Eriguchi Takahisa, Takeda Atsuya, Nemoto Takafumi, Tsurugai Yuichiro, Sanuki Naoko, Tateishi Yudai, Kibe Yuichi, Akiba Takeshi, Inoue Mari, Nagashima Kengo, Horita Nobuyuki
Radiation Oncology Center, Ofuna Chuo Hospital, Kamakura 247-0056, Japan.
Department of Radiation Oncology, Keio University Hospital, Shinjuku, Tokyo 160-8582, Japan.
Cancers (Basel). 2022 Aug 5;14(15):3815. doi: 10.3390/cancers14153815.
Variations in dose prescription methods in stereotactic body radiotherapy (SBRT) for early stage non-small-cell lung cancer (ES-NSCLC) make it difficult to properly compare the outcomes of published studies. We conducted a comprehensive search of the published literature to summarize the outcomes by discerning the relationship between local control (LC) and dose prescription sites. We systematically searched PubMed to identify observational studies reporting LC after SBRT for peripheral ES-NSCLC. The correlations between LC and four types of biologically effective doses (BED) were evaluated, which were calculated from nominal, central, and peripheral prescription points and, from those, the average BED. To evaluate information on SBRT for peripheral ES-NSCLC, 188 studies were analyzed. The number of relevant articles increased over time. The use of an inhomogeneity correction was mentioned in less than half of the articles, even among the most recent. To evaluate the relationship between the four BEDs and LC, 33 studies were analyzed. Univariate meta-regression revealed that only the central BED significantly correlated with the 3-year LC of SBRT for ES-NSCLC ( = 0.03). As a limitation, tumor volume, which might affect the results of this study, could not be considered due to a lack of data. In conclusion, the central dose prescription is appropriate for evaluating the correlation between the dose and LC of SBRT for ES-NSCLC. The standardization of SBRT dose prescriptions is desirable.
早期非小细胞肺癌(ES-NSCLC)立体定向体部放疗(SBRT)中剂量处方方法的差异使得难以恰当地比较已发表研究的结果。我们对已发表文献进行了全面检索,通过辨别局部控制(LC)与剂量处方部位之间的关系来总结结果。我们系统检索了PubMed,以识别报告外周型ES-NSCLC接受SBRT后局部控制情况的观察性研究。评估了LC与四种生物等效剂量(BED)之间的相关性,这四种BED分别根据标称、中心和外周处方点计算得出,并由此计算出平均BED。为评估外周型ES-NSCLC的SBRT相关信息,分析了188项研究。相关文章的数量随时间增加。即使在最近的文章中,也不到一半提及使用不均匀性校正。为评估四种BED与LC之间的关系,分析了33项研究。单变量meta回归显示,只有中心BED与ES-NSCLC的SBRT 3年局部控制显著相关( = 0.03)。作为一个局限性,由于缺乏数据,无法考虑可能影响本研究结果的肿瘤体积。总之,中心剂量处方适用于评估ES-NSCLC的SBRT剂量与局部控制之间的相关性。SBRT剂量处方的标准化是可取的。